Literature DB >> 2899390

Impact of beta-blockade on complex cognitive functioning.

S Streufert1, A DePadova, T McGlynn, R Pogash, M Piasecki.   

Abstract

Fifty adult men with mild to moderate hypertension were recruited to participate in a double-blind crossover study. Each subject received 14 days of drug treatment and 14 days of placebo treatment (random order). Half the subjects were assigned to a metoprolol (150 mg/day) vs placebo treatment regimen and half to an atenolol (100 mg/day) vs placebo regimen. Blood pressure levels as well as measures of simple (proofreading), intermediate (visual-motor task), and complex (management simulation) task performance were obtained at the end of the drug and placebo treatment periods. Metoprolol treatment generated better scores than did placebo or atenolol treatment for proofreading, visual-motor performance, and several measures of complex managerial competence. Atenolol treatment generally resulted in performance levels that did not differ from those observed with placebo. However, atenolol-treated subjects made more errors than did placebo-treated subjects in the visual-motor task and also showed some deterioration on one measure of complex managerial functioning.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899390     DOI: 10.1016/0002-8703(88)90106-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.

Authors:  I J Deary; S Capewell; C Hajducka; A L Muir
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

3.  Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.

Authors:  J Tisaire-Sánchez; J Roma; Ignacio Camacho-Azcargorta; J Bueno-Gómez; J Mora-Maciá; Angel Navarro
Journal:  Vasc Health Risk Manag       Date:  2006

Review 4.  Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.

Authors:  Mirella Russo; Matteo A De Rosa; Dario Calisi; Stefano Consoli; Giacomo Evangelista; Fedele Dono; Matteo Santilli; Alberto Granzotto; Marco Onofrj; Stefano L Sensi
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.